Form F	PTO-1449 (modified)		Atty. Docket No. 4003.002300	Serial No. 10/009,420
List of F	List of Patents and Publications for Applicant's			
OIPE INF	ORMATION DISCLOSURE	Statement	Roy et al.	#3
MAY 0 & JOILT SO	(Use several sheets if neces	sary)	Filing Date: December 4, 2001	Group: 16 35
PRINTE TRADELLES U.			Patent Documents See Page 1	Other Art See Page 1 - 3

U.S. Patent Documents

Exa		Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
F	3	- A1	5,834,440	November 10, 1998	Goldenberg et al.	514	44	
0	P	A2	5,525,468	June 11, 1996	McSwiggen	435	6	
\Box		A3	5,496,698	March 5, 1996	Draper et al.	435	6	

Foreign Patent Documents

	Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
ζ	3	Bl	WO 00/74485	December 14, 2000	PCT	#C		-
0	\\ \\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	B2	WO 99/54459	October 28, 1999	PCT			

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.		Ref. Des.	Citation		
		C1	Amarzguioui and Prydz, "Hammerhead Ribozyme Design and Application," CMLS, 54:1175-1202, 1998.		
		C2	Branch, "A Good Antisense Molecule is Hard to Find," TIBS, 23:45-50, 1998.		
		СЗ	Chen et al., "Catalytic Cleavage of the Androgen Receptor Messenger RNA and Functional Inhibition of Androgen Receptor Activity by a Hammerhead Ribozyme," Mol. Endocrinol., 12(10):1558-1566, 1998.		
		C4	Chen, "Molecular Strategies for Selective Inhibition of Androgen Receptor Gene Expression," A Dissertation presented to the Faculty of The University of Texas Graduate School of Biomedical Sciences at San Antonio in partial fulfillment of the requirements for the Degree of Doctor of Philosophy in Cellular and Structural Biology, March, 1997; Also, Volume 58/03-B of Dissertation Abstracts International, page 1103,1997.		
		C5	Chen and Roy, "Specific Inactivation of the Androgen Receptor Messager RNA by a Hammerhead Ribozyme," <i>Premier Event in 10th International Congress of Endocrinol.</i> , 10:87, 1996.		
$\overline{}$		C6	Cotton and Birnstiel, "Ribozyme Mediated Destruction of RNA in vivo," EMBO J., 8(12):3861-3866, 1989.		

Examiner: 2	DATE CONSIDERED: 9/5/06
EXAMINER: INITIAL IF BEFERENCE CONSIDERED, WHETHER OR NOT CI	TATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THRO
CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE CO	PY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)	Atty. Docket No. 4003.002300	Serial No. 10/009,420	
List of Patents and Publications for Normation Disclosure		Applicant Roy et al.	
(Use several sheets if neces	sary)	Filing Date: December 4, 2001	Group: /6 35
U.S. Patent Documents See Page 1	1	Patent Documents See Page 1	Other Art See Page 1 - 3

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation		
73	C7	Forster and Symons, "Self-Cleavage of Plus and Minus RNAs of a Virusoid and a Structural Model for the Active Sites," Cell, 49:211-220, 1987.		
00	C8	Haseloff and Gerlach, "Simple RNA Enzymes with New and Highly Specific Endoribonuclease Activities," <i>Nature</i> , 334:585-591, 1988.		
	C9	James, "Towards Gene-Inhibition Therapy; A Review of Progress and Prospects in the Field of Antiviral Antisense Nucleic Acids and Ribozymes," Antisense Nucleic Acids and Ribozymes, 2(4):191-214, 1991.		
	C10	Klefstrom et al., "c-Myc Induces Cellular Susceptibility to the Cytotoxic Action of TNF-α," EMBO J., 13(22):5442-5450, 1994.		
	C11	Kobayashi et al., "Reversal of Drug Sensitivity in Multidrug-Resistant Tumor Cells by an MDR1 (PGY1) Ribozyme," Cancer Research, 54:1271-1275, 1994.		
	C12	Lavrovsky et al., "Ribozyme-mediated Cleavage of the Estrogen Receptor Messenger RNA and Inhibition of Receptor Function in Target Cells," Mol. Endocrinol., 13(6):925-934, 1999.		
	C13	L'Huillier et al., "Efficient and Specific Ribozyme-Mediated Reduction of Bovine α- Lactalbumin Expression in Double Transgenic Mice," Proc. Natl. Acad. Sci. USA, 93:6698- 6703, 1996.		
	C14	Marshall, "Gene Therapy's Growing Pains," Science, 269:1050-1055, 1995.		
	C15	Marshall, "Gene Therapy on Trial," Science, 288:951-957, 2000.		
	C16	Milner et al. "Selecting Effective Antisense Reagents on Combinatorial Oligonucleotide Arrays," Nature Biotechnology, 15:537-541, 1997.		
	C17	Pyle, "Ribozymes: A Distinct Class of Metalloenzymes," Science, 261:709-714, 1993.		
	C18	Sarver et al., "Ribozymes as Potential Anti-HIV-1 Therapeutic Agents," Science, 247:1222-1225, 1990.		
	C19	Scanlon et al., "Ribozyme-Mediated Cleavage of c-fos mRNA Reduces Gene Expression of DNA Synthesis Enzymes and Metallothionein," Proc. Natl. Acad. Sci. USA, 88:10591-10595, 1991.		
V	C20	Stull and Szoka, "Antigene, Ribozyme and Aptamer Nucleic Acid Drugs: Progress and Prospects," <i>Pharmaceutical Research</i> , 12(4):465-483, 1995.		

Examiner: 2	DATE CONSIDERED:	9/5/06
EXAMINER: DUTIAL OF PEFERENCE CONSIDERED WHETHER OF NOT C	ITATION IS IN CONTOUNANCE UPTER M	DEDCOO. DO ANY I DIE TUROUCU

Form PTO-1449 (modified)		Atty. Docket No. Serial No. 4003.002300 10/009,420		
List of Patents and Publications for INFORMATION DISCLOSURE ST	•••	Applicant Roy et al.		
(Use several sheets if necessar	ry)	Filing Date: December 4, 2001	Group: /6 35	
U.S. Patent Documents See Page 1	_	Patent Documents See Page 1	Other Art See Page 1 - 3	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.) Exam. Ref. Des. Citation C21 Suzuki et al., "Adenovirus-Mediated Ribozyme Targeting of HER-2neu Inhibits in vivo Growth of Breast Cancer Cells," Gene Therapy, 7:241-248, 2000. C22 Turley et al., "Vitamin E Succinate Induces Fas-Mediated Apoptosis in Estrogen Receptor-Negative Human Breast Cancer Cells," Cancer Research, 57:881-890, 1997. C23 Uhlenbeck, "A Small Catalytic Oligoribonucleotide," Nature, 328596-600, 1987.

International Search Report for PCT/US00/15243, mailed October 4, 2000.

C24

EXAMINER: DATE CONSIDERED: 9/5/66